"Revolutionizing Heart Care & Empowering Patients:" Sirolimus-Driven Balloon Innovation Emerges as a More Effective Alternative to Stents in Larger Arteries
Nov 19, 2025
San Francisco [US], November 19: In a defining chapter for global cardiovascular care, MedAlliance, the Swiss-based innovator behind the patented SELUTION Sirolimus Drug-Eluting Balloon (DEB), continues to transform the landscape of heart disease treatment following its acquisition by Cordis (USA) in October 2023. The landmark USD 1.135 billion (over ₹10,000 crore) transaction stands as a strong endorsement of MedAlliance's breakthrough technology and its far-reaching clinical impact worldwide, including in India.
Read More...
